{"disease":{"id":"pompe-disease","name":"Pompe disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"cipaglucosidase-alfa","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pombiliti","generic_name":"CIPAGLUCOSIDASE ALFA","company_name":"Amicus Therapeutics Europe Limited","drug_phase":"marketed","molecular_target":"Cation-independent mannose-6-phosphate receptor","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Pombiliti works by replacing the deficient acid alpha-glucosidase enzyme in patients with Late-onset Pompe disease."},{"drug_id":"avalglucosidase-alfa-ngpt","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NEXVIAZYME","generic_name":"AVALGLUCOSIDASE ALFA-NGPT","company_name":"GENZYME CORP","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"avalglucosidase-alfa-ngpt","indication_name":"Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NEXVIAZYME","generic_name":"AVALGLUCOSIDASE ALFA-NGPT","company_name":"GENZYME CORP","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"cipaglucosidase-alfa-atga","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"POMBILITI","generic_name":"CIPAGLUCOSIDASE ALFA-ATGA","company_name":"AMICUS THERAP US","drug_phase":"marketed","molecular_target":"Cation-independent mannose-6-phosphate receptor","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"miglustat","indication_name":"Lateonset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavesca","generic_name":"MIGLUSTAT","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"Glucosylceramide Synthase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Zavesca works by inhibiting the enzyme glucosylceramide synthase, which is involved in the production of a toxic lipid that accumulates in cells of patients with certain lysosomal storage disorders."},{"drug_id":"avalglucosidase-alfa","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neogaa","generic_name":"AVALGLUCOSIDASE ALFA","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]","quality_score":55,"revenue":null,"mechanism":"AVALGLUCOSIDASE ALFA breaks down glycogen in lysosomes to treat Pompe disease."},{"drug_id":"avalglucosidase-alfa","indication_name":"Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neogaa","generic_name":"AVALGLUCOSIDASE ALFA","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]","quality_score":55,"revenue":null,"mechanism":"AVALGLUCOSIDASE ALFA breaks down glycogen in lysosomes to treat Pompe disease."}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT00231400","title":"Pompe Disease Registry Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT04981210","title":"High Risk Screen of Childhood Late-onset Pompe Disease in Pediatric Outpatient Clinics","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT04120168","title":"Study Determining the Frequency of Duchenne Muscular Dystrophy and Late-onset Pompe Disease","phase":"","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Turkish Society of Pediatric Gastroenterology, Hepatology and Nutrition","has_results":false},{"nct_id":"NCT06121011","title":"A Global Prospective Observational Registry of Patients With Pompe Disease","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Amicus Therapeutics","has_results":false},{"nct_id":"NCT05619900","title":"Registry of Patients Diagnosed With Lysosomal Storage Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04758130","title":"Getting Global Rare Disease Insights Through Technology Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.A.G.I.C. Clinic LTD","has_results":false},{"nct_id":"NCT03729362","title":"A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT04138277","title":"A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT06150820","title":"A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":119,"lead_sponsor_name":"Astellas Gene Therapies","has_results":false},{"nct_id":"NCT02824068","title":"Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study)","phase":"","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT01710813","title":"Alglucosidase Alfa Pompe Safety Sub-Registry","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT06605612","title":"Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":108,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT02782741","title":"Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT04724213","title":"Development of an Assessment Tool for Health-related Quality of Life in Children and Adolescents With Pompe Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"University Children's Hospital, Zurich","has_results":false},{"nct_id":"NCT05092230","title":"Frequency of Pompe Disease in Patients With Myalgia With or Without Hyper Ckemia - Data From the Reference Center (CERCA)","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University Hospital Center of Martinique","has_results":false},{"nct_id":"NCT05734521","title":"Avalglucosidase Alfa Pregnancy Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05272969","title":"Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":95,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT04907162","title":"Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT02765828","title":"Identification of Tongue Involvement in Late-Onset Pompe Disease","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03893240","title":"Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05073783","title":"A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02746718","title":"Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT05448131","title":"ERT in Pompe Disease: Elucidation of Molecular Structures Contributing to Enzyme Uptake and Immunoreactivity","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Centre for Analytical Biochemistry and Biomedical Mass Spectrometry","has_results":false},{"nct_id":"NCT07478172","title":"Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT06833489","title":"Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT07123155","title":"Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT04676373","title":"Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT05431127","title":"High Dose Inspiratory Muscle Training in LOPD","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05943678","title":"Novel Metabolic Muscular Biomarkers in Pompe Disease - a Non-invasive Magnetic Resonance Exploratory Pilot Study.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT07072676","title":"The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT06130228","title":"Nutritional Therapy in Late-onset Pompe Disease","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT02742298","title":"Pompe Disease QMUS and EIM","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT01380743","title":"Drug-drug Interaction Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT01898364","title":"Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT01230801","title":"Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":true},{"nct_id":"NCT03019406","title":"A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT01435772","title":"Extension Study for Patients Who Have Participated in a BMN 701 Study","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":true},{"nct_id":"NCT01410890","title":"Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT03694561","title":"Developing a Management Approach for Patients With \"Late-Onset\" Pompe Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT00567073","title":"Pompe Pregnancy Sub-Registry","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT05083806","title":"MSOT in Pompe Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT05951790","title":"Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fondazione Don Carlo Gnocchi Onlus","has_results":false},{"nct_id":"NCT03285126","title":"Pompe Gene Therapy- Screening for Eligibility","phase":"","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT02032524","title":"Avalglucosidase Alfa Extension Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT06666413","title":"China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":13,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT02898753","title":"VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Valerion Therapeutics, LLC","has_results":false},{"nct_id":"NCT00486889","title":"Growth and Development Study of Alglucosidase Alfa","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT04476550","title":"Clinical Specimen Collection From Pompe Disease Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Serhat Gumrukcu, MD PhD","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}